~~<i id='99DC6E6C69'><strike id='99DC6E6C69'><tt id='99DC6E6C69'><pre id='99DC6E6C69'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：hotspot 2025-09-29 00:38:27 - browse：6

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Risky weight loss products often used by teens globally, per study

focus

entertainment

Wikipedia

knowledge

explore

focus

RubyWallauforSTATSanofiwilllicenseanewCRISPRenzymefromthestartupScribeTherapeuticsinabidtobethefirst

WSS

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

How dance can help nurses traumatized by Covid

Health and fitness trackers are measuring the wrong things

Startup Neumora takes a novel depression drug to Phase 3

FDA approves RSV monoclonal antibody for infants, toddlers

Custom gene therapy hints at new path for rare disease treatments

hotspot

Wikipedia

focus

Medical records are filled with copy

Google and Epic fight stronger regulation of AI in health care

23andMe had bad news about my health. I wish a person had delivered it

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Hepatitis C has a cure — but many Americans still lack access to it

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Anesthesiologist group: stop taking Ozempic before surgery

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

At least 13 dead in Texas as scorching temps continue

FDA approves RSV monoclonal antibody for infants, toddlers

entertainment

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Cosmetics set for new safety regulation. Why the industry is on board

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Health and fitness trackers are measuring the wrong things

Generative AI mines health records to identify patients’ social needs

Wikipedia

knowledge

explore

focus